Abstract
Multiple sclerosis (MS) is an autoimmune disorder of unknown etiology that causes the immune system to attack the central nervous system. The resultant damage and destruction of nerves causes patients with MS to experience a wide variety of symptoms. Although comorbid conditions are increasing among patients with MS, there is a paucity of research on this issue. This publication addresses this gap in the literature by examining the pharmacological and nonpharmacological interventions for comorbid hypertension in Canadian patients with MS. These interventions can effectively reduce the adverse effects of hypertension in this population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
